Clinical Trial Update: Endogenous Opioid Modulation by Ketamine [Phase 3]

View source ↗

Summary

Phase 3 clinical trial on endogenous opioid modulation by ketamine for major depressive disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Ketamine (ketamine)

Snippet

Sponsor: University of Utah | Conditions: Major Depressive Disorder | Phase 3 | Status: WITHDRAWN